04:41 PM EDT, 07/07/2025 (MT Newswires) -- Inventiva ( IVA ) said late Monday it received a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharm, under their partnership to develop lanifibranor for metabolic diseases in Greater China.

The payment follows the successful settlement of the second tranche of 115.6 million euros ($135.3 million) from Inventiva's ( IVA ) previously announced structured financing package of up to 348 million euros, the company said.

The milestone is part of a 2022 licensing and collaboration agreement under which Chia Tai-Tianqing is developing and commercializing lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH, and related conditions in mainland China, Hong Kong, Macau, and Taiwan.

Inventiva ( IVA ) said it remains eligible for up to $265 million in additional clinical, regulatory, and commercial milestone payments, along with royalties on future sales of lanifibranor, if approved.